JPMorgan Chase & Co. Acquires 45,381 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

JPMorgan Chase & Co. increased its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 419.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 56,199 shares of the biotechnology company’s stock after acquiring an additional 45,381 shares during the quarter. JPMorgan Chase & Co.’s holdings in Capricor Therapeutics were worth $855,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new position in Capricor Therapeutics in the 3rd quarter worth $3,806,000. PFM Health Sciences LP purchased a new stake in Capricor Therapeutics in the third quarter worth about $2,324,000. State Street Corp raised its stake in shares of Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the period. Marshall Wace LLP purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at about $426,000. Finally, Renaissance Technologies LLC grew its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 84,350 shares during the period. 21.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on CAPR shares. HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Piper Sandler began coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of CAPR stock opened at $14.80 on Friday. The company has a market cap of $672.96 million, a PE ratio of -13.96 and a beta of 4.08. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40. The stock’s 50 day simple moving average is $15.06 and its two-hundred day simple moving average is $11.89.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.